Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • lou4012001 lou4012001 Oct 7, 2012 4:57 PM Flag

    Pfizer

    By weeks end....IMHO

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nothing before NCE news and AZN ahead of Pfizer

    • at $24-27

      • 5 Replies to lou4012001
      • Vascepa would be a change in stragegic direction for PFE which currently has no major CVA drugs in their offerings and in 2009 they laid off a large number of the CVA research staff in Groton and sent the remaining activity to Cambridge Mass to essentially by run with MIT.
        I remember the layoff announcements with the CEO stating CVA and Lipid drugs did not appear to have the market potential that PFE wanted to target. I checked with a senior PFE drug rep who indicated they currently have no major branded CVA drugs and that the company had
        minimized that category in its future. Maybe they will go for VAscepa as a fortuitous opportnity but I cant help but think that in 2009 when they were downsizing their activities in this area they knew full well about AMR-101 potential and its relationship with the Jelis study outcomes which we all used to predicted AMR-101 trial outcomes, FDA action and Patent potential. Changing
        strategic direction at a bemouth like PFE is like turning around an Aircraft Carrier doing 30 knots.


        New York, NY - Pfizer is getting out of the cholesterol-lowering game to focus on what it perceives to be more lucrative diseases, according to an internal memo obtained by Forbes [1]. And for the most part, the chosen "disease areas" don't include the heart.

        In the memo, Martin Mackay, president of Pfizer Global Research & Development (R&D), informed his staff that the company plans to "exit" the fields of atherosclerosis/hyperlipidemia, heart failure, obesity, and peripheral arterial disease.

        Instead, the company, whose cholesterol-lowering drug atorvastatin (Lipitor) is the world's top-selling drug, says it is turning its attention and R&D dollars to cancer, diabetes, Alzheimer's, pain remedies, and mental health as its "higher-priority areas."

      • Pfizer is thinking of 22$/share-- Amarin is thinking of 35$/share.
        Goldman Sachs or Lazard would have to bridge the gap to 28$/share.

      • I think Pfizer has initiated talks with Amarin on some kind of relationship--it is like courtship.
        When the talks turn into a final bid--is anyone's guess-- If Lazard is involved,it might move faster.If Goldman sachs was involved,this could be done in 3-4 months. The problem is going to be narrow the gap between BID and ASK.

        Sentiment: Buy

      • I think Pfizer has initiated talks with Amarin on some kind of relationship--it is like courtship.
        When the talks turn into a final bid--is anyone's guess-- If Lazard is involved,it might move faster.If Goldman sachs was involved,this could be done in 3-4 months. The problem is going to be narrow the gap between BID and ASK.

        Sentiment: Buy

 
AMRN
2.39+0.01(+0.42%)Jul 28 4:00 PMEDT